MedPath

Bacillus coagulans LMG S-31876 (ProBC Plus) Demonstrates Immunomodulatory and Stress-Relieving Effects in Clinical Trial

7 months ago2 min read

Key Insights

  • A randomized, double-blind, placebo-controlled trial evaluated Bacillus coagulans LMG S-31876 (ProBC Plus) on immune function and stress in 50 subjects with immune and stress-related ailments.

  • Results showed ProBC Plus significantly improved immune status and aided in stress relief compared to the placebo group over the eight-week study period (p < 0.05).

  • ProBC Plus also exhibited potential cardiovascular support by helping maintain lipid profiles within normal ranges, with vital signs remaining stable throughout the trial.

A recent clinical trial published in Frontiers in Nutrition has revealed that Bacillus coagulans LMG S-31876, marketed as ProBC Plus, demonstrates significant immunomodulatory and stress-relieving effects. The randomized, double-blind, placebo-controlled study, involving 50 participants diagnosed with immune system dysfunction and stress-related disorders, suggests that ProBC Plus could be a safe and effective supplement for improving overall well-being.
The study participants were administered ProBC Plus (2 billion CFU) or a placebo capsule once daily for eight weeks. The primary outcome measures focused on changes in stress levels, immunoglobulin levels, biochemical parameters, and vital signs. Researchers observed a statistically significant (p < 0.05) positive response in the ProBC Plus group regarding stress relief and improved immune status, as indicated by an immune status questionnaire.

Impact on Immune Status and Stress

The trial data indicated a notable improvement in immune status among participants taking ProBC Plus. Enzymatic markers also exhibited a significant decline, suggesting a positive response to the treatment. These findings highlight the potential of Bacillus coagulans LMG S-31876 in modulating the immune system and alleviating stress.

Cardiovascular Support and Safety

In addition to its immunomodulatory effects, ProBC Plus showed promise in maintaining healthy lipid profiles, suggesting potential cardiovascular support. Throughout the study, participants' vital signs remained within normal ranges, reinforcing the safety of ProBC Plus for consumption.

Study Design and Limitations

The clinical trial was registered with the Clinical Trials Registry of India (CTRI/2023/01/048720). While the results are promising, further research with larger sample sizes and diverse populations is warranted to confirm these findings and explore the full potential of Bacillus coagulans LMG S-31876.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.